

Appendix 16.2.6 Individual efficacy response data

List 16.2.6.6 ImmunoCAP ADA; IgG 2

List 16.2.6.6 ImmunoCAP ADA; IgG

Treatment	Subject	TubeID	Time	IgG (mg/L)
Group 1	101	ImmunoCAP ADA. Screening	ADA-Screen	15.2
	101	02AD101Pre	Predose	14.8
	101	02AD10124h	24h after first dose	<2.0
	101	22AD10124h	24h after second dose	<2.0
	101	22AD101d05	5 days after second dose	2.92
	101	22AD101d07	7 days after second dose	19.2
	101	22AD101d14	14 days after second dose	1077
	101	22AD101d21	21 days after second dose	961
	101	22AD101d28	28 days after second dose	768
	101	22AD101d64	64days after second dose	429
	102	ImmunoCAP ADA. Screening	ADA-Screen	12.4
	102	02AD102Pre	Predose	11.2
	102	02AD10224h	24h after first dose	<2.0
	102	22AD10224h	24h after second dose	<2.0
	102	22AD102d05	5 days after second dose	<2.0
	102	22AD102d07	7 days after second dose	3.12
	102	22AD102d14	14 days after second dose	89.8
	102	22AD102d21	21 days after second dose	151
	102	22AD102d28	28 days after second dose	199
	102	22AD102d64	64days after second dose	976
	103	ImmunoCAP ADA. Screening	ADA-Screen	9.77
	103	02AD103Pre	Predose	8
	103	02AD10324h	24h after first dose	<2.0
	103	22AD10324h	24h after second dose	<2.0
	103	22AD103d5	5 days after second dose	<2.0
	103	22AD103d07	7 days after second dose	14
	103	22AD103d14	14 days after second dose	2617
	103	22AD103d21	21 days after second dose	2251

Treatment	Subject	TubeID	Time	IgG (mg/L)
	103	22AD103d28	28 days after second dose	1604
	103	22AD103d64	64days after second dose	368
Group 2	201	ImmunoCAP ADA. Screening	ADA-Screen	10
	201	02AD201Pre	Predose	11
	201	02AD20124h	24h after first dose	<2.0
	201	02AD201d05	5 days after first dose	3
	201	02AD201d07	7 days after first dose	18
	201	02AD201d14	14 days after first dose	186
	201	02AD201d21	21 days after first dose	130
	201	02AD201d28	28 days after first dose	115
	201	02AD201d64	64 days after first dose	104
	203	ImmunoCAP ADA. Screening	ADA-Screen	9
	203	02AD203Pre	Predose	10
	203	02AD20324h	24h after first dose	<2.0
	203	22AD20324h	24h after second dose	<2.0
	203	22AD203d05	5 days after second dose	<2.0
	203	22AD203d07	7 days after second dose	162
	203	22AD203d14	14 days after second dose	646
	203	22AD203d21	21 days after second dose	303
	203	22AD203d28	28 days after second dose	282
	203	22AD203d64	64days after second dose	87
	204	ImmunoCAP ADA. Screening	ADA-Screen	14
	204	02AD204Pre	Predose	12
	204	02AD20424h	24h after first dose	<2.0
	204	02AD204d05	5 days after first dose	2
	204	02AD204d07	7 days after first dose	23
	204	02AD204d14	14 days after first dose	1033
	204	02AD204d21	21 days after first dose	739
	204	02AD204d28	28 days after first dose	607

Treatment	Subject	TubeID	Time	IgG (mg/L)
	204	02AD204d64	64 days after first dose	279
	205	ImmunoCAP ADA. Screening	ADA-Screen	13
	205	02AD205Pre	Predose	11
	205	02AD20524h	24h after first dose	<2.0
	205	22AD20524h	24h after second dose	<2.0
	205	22AD205d05	5 days after second dose	2
	205	22AD205d07	7 days after second dose	3
	205	22AD205d14	14 days after second dose	769
	205	22AD205d21	21 days after second dose	507
	205	22AD205d28	28 days after second dose	385
	205	22AD205d64	64days after second dose	135
Dose interrupted	202	ImmunoCAP ADA. Screening	ADA-Screen	25
	202	02AD202Pre	Predose	24
	202	02AD20224h	24h after first dose	13
	202	02AD202d05	5 days after first dose	12
	202	02AD202d07	7 days after first dose	30
	202	02AD202d14	14 days after first dose	548
	202	02AD202d21	21 days after first dose	397
	202	02AD202d28	28 days after first dose	189
	202	02AD202d64	64 days after first dose	116

Norma AB: Anders Nordlund, Date: 2015-06-25, Time: 11:27
Program: P:\HansaMedical\N8713_13-HMed-IdeS-02\STAT\SASPGM\LIST\ANAL_ADA.sas